多发性骨髓瘤诊治进展 ——写在2019年伊始

doi:10.6040/j.issn.1671-7554.0.2019.362

摘要/Abstract

摘要： 近年来,多发性骨髓瘤的诊断及治疗、疗效评估均进展迅速,新药包括新的蛋白酶体抑制剂、新的免疫调节剂、单克隆抗体以及细胞免疫治疗的出现带来了诊断标准、诊断手段以及疗效评价标准的不断更新。就目前的诊治新进展进行综述,以期指导临床。

关键词: 多发性骨髓瘤, 诊断标准, 疗效评价标准, 治疗

Abstract: The diagnosis, treatment and efficacy evaluation of multiple myeloma are progressing rapidly in recent years. Novel agents including new proteasome inhibitors, new immunomodulators, monoclonal antibodies and cellular therapy have non-stoppingly updated the diagnostic criteria, diagnostic methods and evaluation criteria. This article reviews the current progress in diagnosis and treatment of multiple myeloma in order to guide clinical practice.

Key words: Multiple myeloma, Diagnostic criteria, Evaluation criteria, Treatment

中图分类号:

R733.3

路瑾. 多发性骨髓瘤诊治进展 ——写在2019年伊始[J]. 山东大学学报 (医学版), 2019, 57(7): 40-43.

LU Jin. Advances in the diagnosis and treatment of multiple myeloma[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 40-43.

参考文献

[1] Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J]. Science, 2014,343(6168): 301-305.
[2] Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins [J]. Science, 2014,343(6168): 305-309.
[3] Hansford BG, Silbermann R. Advanced imaging of multiple myeloma bone disease [J]. Front Endocrinol(Lausanne), 2018, 9: 436. doi: 10.3389/fendo.2018.00436.
[4] Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches [J]. Blood, 2019, 133(14): 1534-1539.
[5] Milani P, Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic [J]. Am J Hematol, 2017, 92(8): 772-779.
[6] Moore LM, Cho S, Thoren KL: MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins [J]. Clin Chim Acta, 2019, 492: 91-94. doi: 10.1016/j.cca.
[7] 宋萍, 安志明, 周小钢, 等. 血清游离轻链的检测及其在轻链型多发性骨髓瘤中的临床意义[J]. 中国实验血液学杂志, 2015, 23(5): 1357-1361. SONG Ping, AN Zhiming, ZHOU Xiaogang, et al. Test of serum free light chain and its clinical significance in light chain multiple myeloma [J]. Journal of Experimental Hematology, 2015, 23(5): 1357-1361.
[8] Dejoie T, Corre J, Caillon H, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma [J]. Blood, 2016, 128(25): 2941-2948.
[9] 王亚哲, 路瑾, 郝乐, 等. 4色与8色荧光抗体组合检测多发性骨髓瘤患者微小残留病的比较分析[J]. 中华血液学杂志, 2017, 38(4): 272-278. WANG Yazhe, LU Jin, HAO Le,et al.Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels [J].Chinese Journal of Hematology, 2017, 38(4): 272-278.
[10] Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis [J]. JAMA Oncol, 2017, 3(1): 28-35.
[11] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three pethema/gem clinical trials [J]. J Clin Oncol, 2017, 35(25): 2900-2910.
[12] Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant(SWOG S0777): a randomised, open-label, phase 3 trial [J]. Lancet, 2017, 389(10068): 519-527.
[13] Jacobus SJ, Rajkumar SV, Weiss M, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone(VRd)vs bortezomib-dexamethasone(Vd)for patients with multiple myeloma who have completed a dexamethasone based induction regimen [J]. Blood Cancer J, 2016, 6(7): 448.
[14] Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial [J]. Blood, 2016, 127(21): 2569-2574.
[15] Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial [J]. Leukemia, 2018, 32(2): 383-390.
[16] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J]. N Engl J Med, 2017, 376(14): 1311-1320.
[17] Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma [J]. Blood, 2018, 131(3): 301-310.
[18] 王国苗, 杨光忠, 黄仲夏, 等, 中国多发性骨髓瘤患者接受来那度胺的多中心非干预性前瞻性观察研究[J]. 中华内科杂志, 2017, 56(7): 500-506. WANG Guomiao, YANG Guangzhong, HUANG Zhongxia, et al. A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma [J]. Chinese Journal of Internal Medicine, 2017, 56(7): 500-506.
[19] Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial [J]. Br J Haematol, 2017, 176(5): 743-749.
[20] Facon T. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone(D-Rd)versus lenalidomide and dexamethasone(Rd)in patients with newly diagnosed multiple myeloma(NDMM)ineligible for transplant(MAIA)[J]. ASH abstract LBA-2, 2018.
[21] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [J]. N Engl J Med, 2018, 378(6): 518-528.
[22] ODonnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma [J]. Br J Haematol, 2018, 182(2): 222-230.
[23] Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients[J]. Haematologica, 2019, 7. doi: 10.3324/haematol.
[24] Johnsen HE, Bogsted M, Schmitz A, et al.The myeloma stem cell concept, revisited: from phenomenology to operational terms [J]. Haematologica, 2016, 101(12): 1451-1459.
[25] Lin L, Cao L, Liu Y, et al.B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3 [J]. Leukemia, 2018, 20. doi: 10.1038/s41375-018-0331-6.
[26] Lin L, Zhang X, Cao L, et al. Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin beta1 signaling [J]. J Cancer, 2017, 8(12): 2212-2222.
[27] Lakshman A, Painuly U, Rajkumar SV, et al. Natural history of multiple myeloma with de novo del(17p)[J]. Blood Cancer J, 2019, 9(3): 32.
[28] Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies [J]. Expert Rev Hematol, 2018, 11(11): 863-879.
[29] Lagana A, Beno I, Melnekoff D, et al. Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach [J]. JCO Precis Oncol, 2018. doi: 10.1200/PO.18.00019.
[30] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy [J]. Cancer Cell, 2014, 25(1): 91-101.
[31] Harding T, Baughn L, Kumar S, et al. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies [J]. Leukemia, 2019, 33(4): 863-883.
[32] Matulis SM, Gupta VA, Neri P, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma [J]. Leukemia, 2019, 33(5): 1291-1296.
[33] Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma [J]. Leukemia, 2016, 30(4): 976-980.

相关文章 15

[1]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2]	孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62.
[3]	林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[4]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[5]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[6]	河南省生物医学工程学会立体心电图专业委员会,中国医药教育协会心电学专业委员会,山东中医药学会心电学专业委员会,青岛市医学会心电生理与起搏专科分会,全国医药技术市场协会远程心脏专业委员会. 心电向量图诊断标准规范化专家共识(2025)[J]. 山东大学学报 (医学版), 2025, 63(7): 1-10.
[7]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.
[8]	赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 ¹³¹I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28.
[9]	韩馨玮,牛月,魏代敏. 激素替代方案准备内膜的冻胚移植前雌激素治疗时间对新生儿体质量的影响[J]. 山东大学学报 (医学版), 2025, 63(11): 46-52.
[10]	黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[11]	薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19.
[12]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[13]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[14]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[15]	陈忠,王盛. 主动脉疾病治疗现状及思考[J]. 山东大学学报 (医学版), 2024, 62(9): 1-6.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed